

## OBSERVATIONS

## Prevalence and Risk Factors of Diabetic Foot Problems in Taiwan

A cross-sectional survey of non-type 1 diabetic patients from a nationally representative sample

About half of all nontraumatic lower extremity amputations are performed on diabetic patients (1,2), and foot ulcers precede 71–84% of all lower extremity amputations (3,4). In the Caucasian population, 15% of diabetic patients will develop a foot ulcer during their lifetime (5), and 6–43% of diabetic patients with a foot ulcer will eventually progress to lower extremity amputation (3,4,6). To this author's knowledge, there has not been any previous nationwide epidemiologic survey on diabetic foot problems in Taiwan, and the clinical outcomes of diabetic foot ulcers are still unknown.

To survey diabetic foot problems in the Taiwanese population, a total of 16,994 non-type 1 diabetic patients were randomly selected for telephone interview from a group covered by the National Health Insurance (>96% of the total population is covered by this health care system). They were questioned on whether they had diabetic foot problems, as indicated by ulcer, gangrene, or amputation on the lower extremities. Lifetime prevalence was calculated, and various risk factors were analyzed. A total of 12,531 case subjects (response rate 73.7%) were successfully interviewed. Diabetic foot problems were present in 369 patients (prevalence 2.9%) with 540 initiating events. Ulcers represented 86.7% of all initiating events. Approximately 26.9% of the ulcers progressed to gangrene or amputation, and ulcers preceded 71.9% of all amputations. In univariate analyses, diabetic foot problems were characterized by older age, male preponderance, longer duration of diabetes, smoking, poorer glycemic control, more insulin users, hypertension, hyperlipidemia, higher diastolic and systolic blood

pressure, lower education level, and living in rural areas. In logistic regression, the multivariate-adjusted odds ratios (95% CI) were significant for men 1.461 (1.063–2.008); duration of diabetes 1.048 (1.033–1.063); insulin therapy 2.921 (2.199–3.881); education level (vs. a high school education or higher) 1.450 (1.089–1.931) and 2.194 (1.543–3.121) for elementary school and illiteracy, respectively; ex-smokers <5 years versus nonsmokers 1.645 (1.030–2.627); systolic blood pressure 1.019 (1.008–1.030); and hyperlipidemia 1.478 (1.117–1.956). In conclusion, diabetic foot problems are present in 2.9% of Taiwanese non-type 1 diabetic subjects. Although foot ulcers are less common among Taiwanese than Caucasian subjects, the outcomes are not better. Conventional risk factors for atherosclerosis are important, but particular attention should be focused on patients with a lower education level and those who use insulin.

CHIN-HSIAO TSENG, MD, PHD

From the Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; the National Taiwan University College of Medicine, Taipei, Taiwan; and the Division of Environmental Health and Occupational Medicine of the National Health Research Institutes, Taipei, Taiwan.

Address correspondence to Chin-Hsiao Tseng, MD, PhD, Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Rd., Taipei, Taiwan. E-mail: ccktsh@ms6.hinet.net.

© 2003 by the American Diabetes Association.

### References

1. Tseng CH, Tai TY, Chen CJ, Lin BJ: Ten-year clinical analysis of diabetic leg amputees. *J Formos Med Assoc* 93:388–392, 1994
2. The Global Lower Extremity Amputation Study Group: Epidemiology of lower extremity amputation in centers in Europe, North America and East Asia. *Br J Surg* 87:328–337, 2000
3. Moss SE, Klein R, Klein B: Long-term incidence of lower-extremity amputations in a diabetic population. *Arch Fam Med* 5:391–398, 1996
4. Larsson J, Agardh CD, Apelqvist J, Stenstrom A: Clinical characteristics in relation to final amputation level in diabetic patients with foot ulcers: a prospective study of healing below or above the ankle in 187 patients. *Foot Ankle Int* 16:69–74, 1995

5. Reiber GE, Lipsky BA, Gibbons GW: The burden of diabetic foot ulcers. *Am J Surg* 176 (Suppl. 2A):5S–10S, 1998
6. Apelqvist J, Ragnarson-Tennvall G, Persson U, Larsson J: Diabetic foot ulcers in a multidisciplinary setting: an economic analysis of primary healing and healing with amputation. *J Intern Med* 235:463–471, 1994

## Nonalcoholic Fatty Liver Disease in Saudi Type 2 Diabetic Subjects Attending a Medical Outpatient Clinic

Prevalence and general characteristics

Nonalcoholic fatty liver disease (NAFLD) is a liver condition that is being recognized with increasing frequency, and it may progress to end-stage liver disease (1). NAFLD can affect any age-group and has been described in most racial groups. In most series, the typical picture is a middle-aged woman (1). Obesity has the strongest association with NAFLD, but regardless of BMI, the presence of type 2 diabetes significantly increases the risk and severity of NAFLD. The prevalence of NAFLD in the general population ranges from 13 to 15% (2). The prevalence increases in subjects with diabetes and with severe obesity and has been reported to range from 25 to 75% or even higher (3). In Saudi Arabia, a prevalence of 7–10% has been reported in the general population (4,5). The aim of our work is to determine the prevalence and characteristics of NAFLD in Saudi type 2 diabetic subjects attending King Abdulaziz University Hospital. A sample of 116 patients was randomly selected over 1 year. All participants provided informed consent before participation. The entire sample had an abdominal ultrasound examination (using an ATL HDI 5000 abdominal probe at 2.5–3 MHz) and liver enzyme measurement performed. The sonographic findings used to diagnose NAFLD were diffuse increase in echogenicity of the liver parenchyma, which is assessed by absence of hyperechoic walls

of the portal vein radicals, and absence of interface between diaphragm and liver. All radiological examinations were done by the same radiologist. The upper limit of normal liver size was 16 cm in the longitudinal plane; any measurement above this was considered hepatomegaly. Mild hepatomegaly was defined as liver size >16–18 cm in the longitudinal plane. Secondary causes of liver disease were excluded, in particular ethanol abuse (the sample studied did not drink alcohol) and use of drugs known to promote hepatic steatosis. In patients with elevated liver enzymes, those who used hepatotoxic drugs were excluded.

The mean age of the study group was  $54 \pm 12.8$  years with a male-to-female ratio of 1:2.6. The mean duration of diabetes was  $8.85 \pm 6.18$  years, mean BMI was  $30 \pm 5.5$  kg/m<sup>2</sup>, and HbA<sub>1c</sub> was  $7.9 \pm 1.1\%$ . NAFLD was diagnosed in 64 (55%) subjects. Right upper quadrant discomfort was reported in 11 of 64 (17%) subjects and elevated liver enzymes were found in 12 of 64 (19%). Mean aspartate aminotransferase level was  $23.75 \pm 10.3$  units/l (normal range 5–65 units/l), alanine aminotransferase  $71 \pm 22.04$  units/l (normal range 5–38 units/l), and alkaline phosphatase  $112.62 \pm 58.13$  units/l (normal range 35–136 units/l). Fifty-six (88%) subjects had hepatomegaly as assessed by ultrasound, which was mild in two-thirds of them. None of the patients without NAFLD had hepatomegaly. The average liver size was  $17.2 \pm 3.1$  cm in patients with fatty infiltration and  $13 \pm 2.4$  cm in non-NAFLD patients. A significant relationship was found between the presence of NAFLD and female sex ( $P = 0.05$ ). No significant relationship was found between the presence of NAFLD and age, duration of diabetes, or degree of glycemic control. Multiple regression analysis after adjustment for all factors and sex identified obesity as an independent factor associated with the development of NAFLD ( $P = 0.06$ ).

Our results agree with those reported in the literature. The natural history of NAFLD has not been well defined, but it seems to be determined by the severity of histological damage (2). Hepatomegaly with mild to moderate elevation in serum levels of transaminases has been reported; however, this doesn't correlate with liver histology (1,6). Future prospective studies need to clarify whether diabetic sub-

jects have the same natural history, i.e., whether they are affected by the same histological changes or have other additional factors that may play a role, such as insulin resistance or type of treatment.

We can conclude that NAFLD, as determined by ultrasound, is common in Saudi type 2 diabetic subjects. As in reports from other ethnic groups, female sex and obesity were the two predominant features of patients with NAFLD in Saudi Arabia. In this small cohort of patients, neither glycemic control nor duration of diabetes had any relationship with fatty liver infiltration. This suggests that factors other than hyperglycemia operate to cause hepatic steatosis.

DAAD H. AKBAR, FRCP, FACP  
ABEER H. KAWTHER, FRCP, FACP

From the Department of Medicine, King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia.

Address correspondence to Dr. Daad H. Akbar, Associate Professor/Consultant Physician, P.O. Box 127191, Jeddah 21352, Saudi Arabia. E-mail: daadakh@yahoo.com.

© 2003 by the American Diabetes Association.

## References

- Ludwig J, Viggiano TR, McGill DB, Oh BJ: Non alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clinic Proc* 55:434–438, 1980
- Teli MR, James OF, Burt AD, Bennett MK, Day CP: The natural history of nonalcoholic fatty liver: a follow-up study. *Hepatology* 22:1714–1719, 1995
- McCullough AJ: Update on nonalcoholic fatty liver disease. *J Clin Gastroenterol* 3:255–262, 2002
- al-Quorain A, Satti MB, al-Hamdan AR, al-Gindan Y, Ibrahim E, Khatib R, al-Freih H: Pattern of chronic liver disease in the eastern province of Saudi Arabia: a hospital-based clinicopathological study. *Trop Geogr Med* 46:358–360, 1994
- El-Hassan AY, Ibrahim EM, al-Muhim FA, Nabhan AA, Chammas MY: Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. *Br J Radiol* 65:774–778, 1992
- Van Ness MM, Diahl AM: Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? *Ann Intern Med* 11:473–478, 1989

## Prospective Audit of the Introduction of Insulin Glargine (Lantus) Into Clinical Practice in Type 1 Diabetic Patients

Insulin glargine is a modified basal insulin analog that has been recently introduced, and following guidance from the National Institute for Clinical Excellence (NICE), it is now widely available in the U.K. (1). Studies in type 1 diabetes demonstrate that compared with NPH insulin, fasting blood glucose and hypoglycemic episodes are reduced and patient satisfaction is improved (2–7). To confirm whether these reported benefits are also achieved in routine clinical practice, we conducted a prospective audit of patients attending our diabetes clinic practice transferring to insulin glargine.

There were 83 patients with type 1 diabetes on multiple daily injection regimens who were transferred from NPH insulin to insulin glargine between July and November 2002. Indications for transfer were nocturnal hypoglycemia, morning fasting hyperglycemia, the use of two NPH injections, or patient request. Patient details, including glycemic control (glucose concentrations and HbA<sub>1c</sub> levels), were recorded. Patients completed a questionnaire on the frequency of hypoglycemia (requiring corrective action by patient) over the preceding month and severe hypoglycemic episodes (requiring assistance from a third party) over the 3 months preceding the initiation of insulin glargine therapy. Patient assessments on quality of life and well-being (Diabetes Treatment Satisfaction Questionnaire and Well-Being Questionnaire 28) (8,9) were also performed. Patients were reassessed after receiving insulin glargine for 3 months.

Morning blood glucose concentrations and HbA<sub>1c</sub> levels fell significantly, from  $9.63 \pm 0.44$  to  $7.15 \pm 0.28$  mmol/l ( $P < 0.001$ ) and from  $8.24 \pm 0.16$  to  $7.86 \pm 0.11\%$  ( $P = 0.006$ ), respectively. Total hypoglycemic episodes remained unchanged after transferral to insulin glargine. The number of severe hypoglycemic episodes was not statistically significantly different after transfer to glargine from baseline values (from 15 to 7) ( $P =$

0.077). Aggregate scores for the Diabetes Treatment Satisfaction Questionnaire, which reflect satisfaction with treatment, improved from 23.5 (0.68) to 28 (0.67) ( $P < 0.001$ ), whereas the score for unacceptably high blood glucose values fell from 3.53 (0.16) to 2.83 (0.17) ( $P = 0.002$ ) with no significant change for unacceptably low blood glucose values (from 2.43 [0.16] to 2.11 [0.14]) ( $P = 0.07$ ). The scores for the Well-Being Questionnaire 28 show significant improvements in patient-reported energy levels ( $P < 0.001$ ), diabetes-specific well-being ( $P = 0.044$ ), and total well-being ( $P = 0.001$ ), with significant reductions in diabetes-related stress ( $P = 0.014$ ).

Our results confirm that people with type 1 diabetes on a multiple daily insulin injection regime who transfer to insulin glargine from isophane insulin have a significant fall in their morning blood glucose concentrations and HbA<sub>1c</sub> levels as well as significant improvements in satisfaction with their treatment and subjective well-being. The use of insulin glargine appears to be advantageous for some patients with type 1 diabetes.

IAN W. GALLEN, MD, FRCP  
CELIA CARTER, RGN

From the South Buckinghamshire National Health Services Trust, Wycombe Hospital, Buckinghamshire, U.K.

Address correspondence to Dr. Ian Gallen, Diabetes Centre, Wycombe Hospital, High Wycombe, Buckinghamshire HP11 2TT, U.K. E-mail: ian.gallen@sbucks.nhs.uk.

© 2003 by the American Diabetes Association.

## References

1. National Institute for Clinical Excellence: *Technology Appraisal Guidance: Guidance on the Use of Long-Acting Insulin Analogues for Treatment of Diabetes: Insulin Glargine*. London, National Institute for Clinical Excellence, 2002 (no. 53)
2. Pieber TR, Eugene-Jolchine I, Derobert E: Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes: the European Study Group of HOE 901 in type 1 diabetes. *Diabetes Care* 23: 157–162, 2000
3. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T: A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. *Diabetes Care* 23: 1666–1671, 2000
4. Rosenstock J, Park G, Zimmerman J, the US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group: Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. *Diabetes Care* 23: 1137–1142, 2000
5. Porcellati F, Rossetti P, Fanelli C, Scionti L, Brunetti P, Bolli GB: Glargine vs NPH as basal insulin in intensive treatment of type 1 diabetes mellitus given lispro at meals: one year comparison (Abstract). *Diabetes* 51: (Suppl. 2):A53, 2002
6. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA, the US Study Group of Insulin Glargine in Type 1 Diabetes: Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. *Diabetes Care* 23:639–643, 2000
7. Witthaus E, Stewart J, Bradley C: Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. *Diabet Med* 18:619–625, 2001
8. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R: The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. *Qual Life Res* 8:79–91, 1999
9. Speight J, Bradley C: The W-BQ28 measure of generic and diabetes-specific well-being is shown to be valid, reliable and sensitive to change in DIABQoL+ and DAFNE studies. *Diabet Med* 19:10, 2002

## Self-Blood Glucose Monitoring Practices

Do patients know and act on their target?

**S**elf-monitoring of blood glucose (SMBG) is a major advance in diabetes care, but questions remain about its exact role in type 2 diabetes (1). Studies conducted in large clinical practices have shown a positive association between SMBG frequency and good glycemic control in patients with type 2 diabetes. However, few attempts to describe the relationship between monitoring and glycemic control have looked beyond the frequency of testing to determine whether patients clearly understood their target values and how they respond to the information obtained from monitoring (2–4).

In a collaborative effort, the Great Falls Clinic and the Montana Department of Public Health and Human Services sur-

veyed a random sample of current patients with diabetes (815 of 1,234 patients were selected) by telephone in October 2002, to assess their diabetes care. Respondents were asked if they were currently taking insulin and/or oral antihyperglycemic medications and were classified into three groups: those using insulin with or without oral antihyperglycemic agents, those taking oral therapies only, and those not currently taking any diabetes medications. Respondents were also asked about SMBG, “About how often do you check your blood for glucose or sugar?” (the response categories for this question were the number of times per day, week, month, or year, or don’t know/not sure, never, and refused to answer). Respondents reporting any SMBG were then asked, “What do you do with your blood glucose or sugar readings when they are too high? Do you adjust your medication? Do you eat less food?” Respondents who monitored were also asked, “What do you do with your blood glucose or sugar readings when they are too low? Do you adjust your medication? Do you take more food?” And finally, those who reported any SMBG were asked, “What is your target blood glucose or sugar value?”

The most recent A1c values were matched to the information collected from the telephone survey. A1c testing was performed by a central laboratory using the BioRad Variant II (BioRad, Hercules, CA), a high-pressure liquid chromatography method (normal range 4.0–6.0%). Data analyses were conducted using SPSS v10.0 software. Pearson  $\chi^2$  tests were used to compare SMBG practices by medication type, and Kruskal-Wallis tests were used to compare the median A1c value among respondents by SMBG target and medication type. Nonparametric statistical tests were used in these analyses because the A1c values were not normally distributed.

Of the 815 patients, 61% completed the survey. There were no statistically significant differences between respondents and nonrespondents by age (mean age 62.3 vs. 61.5 years,  $P = 0.49$ ), sex (male 55 vs. 48%,  $P = 0.07$ ), or by the last A1c value (median A1c value 7.2 vs. 7.3%,  $P = 0.12$ ). Thirty-seven percent of respondents used insulin (27% insulin alone and 10% in combination with oral agents), 49% used oral medications only, and 14% were taking no antihyperglyce-

mic medications. Respondents using insulin were more likely to monitor daily (52%) compared with those taking oral medication only (30%) and those taking no medication (7%,  $P < 0.001$ ). Those using insulin were also more likely to report an SMBG target (88%) compared with respondents taking oral therapy only (70%) or those taking no medication (42%,  $P < 0.001$ ).

Among respondents using insulin, a larger proportion of those reporting a blood glucose target took some action (i.e., adjusted medication and/or ate more/less food) when their blood glucose values were low compared with those without a target (90 vs. 71%,  $P = 0.02$ ). However, there were no differences between the two groups regarding actions taken when the glucose values were high (86 vs. 77%,  $P = 0.27$ ). Among respondents taking oral medications only, those with a blood glucose target were also more likely than those without a target to take some action when their blood glucose values were low (63 vs. 46%,  $P = 0.03$ ), but not when they were high (65 vs. 64%,  $P = 0.82$ ). For respondents taking no medications, those with blood glucose targets were no more likely to take any action (i.e., eat more/less food) when their blood glucose values were high (67 vs. 33%,  $P = 0.06$ ) or low (50 vs. 40%,  $P = 0.57$ ) compared with those who did not report a target.

The median target blood glucose value reported was 120 (25th percentile = 105, 75th percentile = 130). Individuals using insulin reporting targets  $\leq 120$  had a significantly lower median A1c values (median 7.3%) compared with those with SMBG targets  $> 120$  (8.3) and those with no target (8.7,  $P = 0.02$ ). There was a small but not significant difference in the median A1c values among respondents taking oral medications in those with targets  $\leq 120$  (7.1) compared with those reporting targets  $> 120$  (7.3) or those with no target (7.0,  $P = 0.07$ ). But, there were no differences in the median A1c values regardless of a reported target or the level of the target among those taking no diabetes medications (6.1 for each medication group,  $P = 0.29$ ).

This is one of very few studies to look beyond the frequency of SMBG and ask how patients understood and utilized their values before looking at the relationship of monitoring to glycemic control. Many patients with diabetes who moni-

tored did not know their blood glucose targets. Among those taking insulin, lower targets were clearly associated with better metabolic control. The relationships between targets and metabolic control were not as clear among patients taking only oral medications or those taking no medications. However, our sample was small, and we could not distinguish recently diagnosed individuals from long-term patients. The cross-sectional design of this study precludes determining whether awareness of glycemic targets led to better glycemic control versus achievable targets that were tailored to each patient's level of glycemic control (e.g., patients in poor control were given high and more achievable glycemic targets by their provider). Longitudinal studies are needed to address this issue.

Thus, the role of SMBG in type 2 diabetes will likely depend on both the therapies used to control hyperglycemia and what both patients and health care providers do with the values. Finally, the SMBG frequency for individuals with type 2 diabetes to maintain optimal A1c levels for a given therapy may be different from the frequency needed to adjust therapy to reach a target. (5) We have previously shown that patients with diabetes did not always know their A1c value or its meaning (6). Similarly, in this study patients with diabetes did not always have a clear understanding of what blood glucose levels they should be trying to achieve.

DEB K. BJORSNESS, MPH, RD, CDE<sup>1</sup>

PHILIP A. KREZOWSKI, MD<sup>1</sup>

TODD S. HARWELL, MPH<sup>2</sup>

JANET M. McDOWALL, RN, BSN<sup>2</sup>

MARCENE K. BUTCHER, RD, CDE<sup>2</sup>

STEVEN D. HELGERSON, MD, MPH<sup>2</sup>

DOROTHY GOHDES, MD<sup>2</sup>

From the <sup>1</sup>Great Falls Clinic, Great Falls, Montana; and the <sup>2</sup>Montana Department of Public Health and Human Services, Helena, Montana.

Address correspondence to Todd S. Harwell, MPH, Montana Department of Public Health and Human Services, Cogswell Bldg., C-317, P.O. Box 202951, Helena, MT 59620-2951 E-mail: tharwell@state.mt.us.

D.G. has received honoraria or consulting fees from NovoNordisk, Aventis, and GlaxoSmithKline.

© 2003 by the American Diabetes Association.

**Acknowledgments**— This project was supported through cooperative agreements (U32/CCU815663-05) with the Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, Georgia. The contents of

this report are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.

We thank Linda Priest and the staff members of Northwest Resource Consultants for their expertise and work on the telephone survey. We also thank Susan Day for her assistance throughout this project.

## References

1. Nathan DM, McKittrick C, Larkin M, Schaffran R, Singer DE: Glycemic control in diabetes mellitus: have changes in therapy made a difference? *Am J Med* 100:157–163, 1996
2. Karter AJ, Ackerson LM, Darbinian JA, D'Agostino RB, Ferrara A, Liu J, Selby J: Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes Registry. *Am J Med* 111:1–9, 2001
3. Blonde L, Ginsberg BH, Horn S: Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes (Letter). *Diabetes Care* 25: 245–246, 2002
4. Patrick AW, Gill GV, MacFarlane IA, Cullen A, Power E, Wallymahmed M: Home glucose monitoring in type 2 diabetes: is it a waste of time? *Diabet Med* 11:62–65, 1994
5. Murata GH, Shah JH, Hoffman RM, Wendel CS, Adam KD, Solvas PA, Bokhari SU, Duckworth WC: Intensified blood glucose monitoring improves glycemic control in stable, insulin-treated veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). *Diabetes Care* 26:1759–1763, 2003
6. Harwell TS, Dettori N, McDowall JM, Quesenberry K, Priest L, Butcher MK, Flook BN, Helgerson SD, Gohdes D: Do persons with diabetes know their (A1C) number? *Diabetes Educ* 28:99–105, 2002


## The Cutoff Value of Fasting Plasma Glucose to Differentiate Frequencies of Cardiovascular Risk Factors in a Korean Population

**D**iabetes and impaired glucose tolerance (IGT) are associated with increased cardiovascular mortality. Almost all studies, however, failed to de-

tect evidence of the presence of a fasting plasma glucose (FPG) threshold for risk of cardiovascular disease that would clearly identify groups with a low or high risk (1,2). Some studies suggested that an FPG of 5.4–5.7 mmol/l has been found to be closer to a 2-h cutoff of 7.8 mmol/l both in terms of the sensitivity for future diabetes and in defining a category of similar prevalence to IGT (3,4). The interrelationships between cardiovascular risk factors and glucose levels may vary between different populations. Therefore, these findings need to be tested in other populations with different environmental and genetic backgrounds.

The medical records of 54,623 subjects (30,435 men and 24,188 women) who attended the Health Promotion Center in the Samsung Medical Center between 1998 and 2001 were examined for this analysis. Obesity was defined as a BMI  $\geq 27$  kg/m<sup>2</sup>. Hypertension was defined as systolic blood pressure  $\geq 140$  mmHg, diastolic blood pressure  $\geq 90$  mmHg, and/or the current use of antihypertensive drugs. Dyslipidemia was defined as LDL cholesterol  $\geq 4.1$  mmol/l, triglycerides  $\geq 2.46$  mmol/l, HDL cholesterol  $< 1.04$  mmol/l, and/or current use of antilipid drugs. Cases of previous history of diabetes were excluded.

All study subjects were classified into 12 groups according to FPG (10 deciles of normal fasting glucose [NFG]: NFG 1,  $< 4.56$ ,  $n = 5,370$ ; NFG 2, 4.57–4.72,  $n = 4,495$ ; NFG 3, 4.73–4.89,  $n = 6,321$ ; NFG 4, 4.90–5.00,  $n = 4,655$ ; NFG 5, 5.01–5.11,  $n = 4,841$ ; NFG 6, 5.12–5.22,  $n = 4,503$ ; NFG 7, 5.23–5.33,  $n = 4,233$ ; NFG 8, 5.34–5.50,  $n = 5,236$ ; NFG 9, 5.51–5.72,  $n = 4,926$ ; NFG 10, 5.73–6.09,  $n = 4,230$ ; IFG, 6.10–6.99,  $n = 3,587$ ; and diabetes,  $\geq 7.00$  mmol/l,  $n = 2,226$ ). Those with an FPG  $\leq 4.56$  mmol/l formed the lowest group, and those with FPG  $> 7.0$  mmol/l formed the highest group. Frequencies of obesity in each group were 5.2, 6.7, 8.2, 8.9, 9.2, 10.9, 11.1, 12.9, 14.5, 17.0, 19.0, and 20.3%, respectively. Those of hypertension were 11.3, 13.2, 15.0, 16.6, 18.2, 20.1, 22.9, 23.2, 27.4, 32.8, 37.8, and 37.4%, respectively. Finally, those of dyslipidemia were 25.0, 29.0, 31.5, 34.7, 36.3, 39.3, 41.7, 42.6, 47.5, 52.8, 58.6, and 67.0%, respectively. After controlling for age and sex and odds ratio (OR) for obesity, hypertension and dyslipidemia in the IFG group were 4.04 (3.43–4.75), 2.80



**Figure 1**—ORs of obesity, hypertension, and dyslipidemia according to FPG value, with subjects with FPG  $\leq 4.56$  mmol/l as the referent group. Data are ORs and 95% CI. \*P  $< 0.05$ ; \*\*P  $< 0.01$  vs. subjects with one level lower FPG.

(2.48–3.17), and 2.74 (2.47–3.04), respectively, with FPG subjects  $\leq$ 4.56 mmol/l (NFG1) as the referent group. Those in the diabetes group were 4.29 (3.59–5.13), 2.65 (2.31–3.04), and 4.13 (3.66–4.67) (Fig. 1). Although there was no clear cutoff point to differentiate the risk of obesity, a threshold at an FPG value of 5.34–5.50 mmol/l was suggested. For hypertension and dyslipidemia, more clear threshold values were observed. The group with an FPG value of 5.51–5.72 mmol/l had a considerably greater OR of hypertension and dyslipidemia than the group with an FPG value of 5.34–5.50 mmol/l.

The data clearly showed that even in the NFG range, the level of fasting glucose was closely related to the frequencies of cardiovascular risk factors, including obesity, hypertension, and dyslipidemia, and strongly suggested the significance of a concentrated effort to reduce the cardiovascular risk factors in the earlier stage of an FPG  $<$ 6.10 mmol/l in a Korean population.

DONG-JUN KIM, MD<sup>1</sup>  
 KWANG-WON KIM, MD, PHD<sup>2</sup>  
 NAM-HAN CHO, MD, PHD<sup>3</sup>  
 JUNG-HYUN NOH, MD, PHD<sup>1</sup>  
 MYUNG-SHIK LEE, MD, PHD<sup>2</sup>  
 MOON-KYU LEE, MD, PHD<sup>2</sup>

From the <sup>1</sup>Department of Internal Medicine, Inje University College of Medicine, Koyang, Korea; the <sup>2</sup>Department of Medicine, Division of Endocrinology and Metabolism, Sungkyunkwan University School of Medicine, Seoul, Korea; and the <sup>3</sup>Department of Preventive Medicine, Ajou University School of Medicine, Suwon, Korea.

Address correspondence to Prof. Kwang-Won Kim, Sungkyunkwan University School of Medicine, Department of Medicine, Division of Endocrinology & Metabolism, Samsung Medical Center, 50 Ilwon-dong, Kangnam-ku, Seoul 135-710, Korea. E-mail: kwwkim@smc.samsung.co.kr.

© 2003 by the American Diabetes Association.



References

1. Balkau B, Ducimetiere P, Bertrais S, Eschwege E: Is there a glycemic threshold for mortality risk? *Diabetes Care* 22:696–699, 1999
2. The DECODE study group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? *Diabetes Care* 26:688–696, 2003
3. Shaw JE, Zimmet PZ, Hodge AM, Courten M, Dowse GK, Chitson P, Tuomilehto J, Alberti KGMM: Impaired fasting glucose: how low should it go? *Diabetes Care* 23:

34–39, 2000

4. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Rouamin J, Bennet PH, Knowler WC: The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. *Diabetes Care* 23:1108–1112, 2000

**Safety Issues on Metformin Use**

We read with interest the letter by Faichney and Tate (1) in the May issue of *Diabetes Care*. We would like to comment on metformin and the risk of lactic acidosis; however, we do not have data to refute the hypothetical relevance of diabetic ketoacidosis to the risk of lactic acidosis (1). We believe that the aforementioned letter and relevant reports (2–4) may negatively affect the future use of metformin, not only in type 1 (1) but also in type 2 diabetic patients. In this regard, the report by Horlen et al. (2), which addressed physicians' lack of adherence to metformin prescribing precautions, was received with strong opposition in the medical media (5) following the public support from the Associated Press ([www.ace.com](http://www.ace.com)).

Lactic acidosis has been linked to the use of biguanides for decades. Although phenformin had been pulled from the market, metformin-associated lactic acidosis has since been believed to be the direct result of metformin use, especially in situations likely to precipitate lactic acidosis, e.g., congestive heart failure, chronic renal insufficiency, shock, etc. Although this "solid fact" of causative (etiologic) relation between metformin and lactic acidosis has not been challenged previously, recent relevant publications have appeared in the literature (6–8). Lallau and colleagues (6,7) found that metformin accumulation was not related to either lactic acidosis or the associated mortality in patients taking therapeutic doses of metformin who developed lactic acidosis in association with other precipitating conditions. Metformin overdose was an exception, they reported (6); the latter can cause genuine type B lactic acidosis, but only a few such cases have been reported (9). In the report on metformin-associated lactic acidosis published by

FDA investigators (3), metformin levels were not measured.

Rachmani et al. (8) have recently reported no lactic acidosis in diabetic patients who were continued on metformin over 4 years of follow-up; these patients had traditional contraindications (congestive heart failure, chronic renal insufficiency, or chronic obstructive pulmonary disease) to metformin use. Furthermore, a recent meta-analysis of 176 studies with  $>$ 35,000 patient-years of follow-up found no cases of lactic acidosis, although some of these studies included patients with renal insufficiency and cardiovascular conditions (4).

Finally, Jones and Macklin (10) have recently reported that evidence suggested it was time to amend the contraindication "list" of metformin prescribing. They pointed out that the limiting criteria for the use of metformin in diabetes had stemmed largely from reports in the 1970s of mortality and lactic acidosis associated with "phenformin."

Therefore, one may wonder whether metformin is an "innocent bystander" in these clinically complex metformin-associated lactic acidosis cases.

In conclusion, in view of the aforementioned thoughts challenging the "apparently well-established" etiologic role of metformin in metformin-associated lactic acidosis, and pending further research, it is prudent to critically appraise published reports on the issue. We believe that the average dose of metformin currently used in clinical practice is reasonably safe, even in the presence of mild to moderate cases of the "traditional contraindications." An exception to this is the safe practice of holding metformin before contrast studies and during acute, intercurrent illnesses.

SALEH A. ALDASOUQI, MD<sup>1</sup>  
 DANIEL S. DUICK, MD<sup>2</sup>

From the <sup>1</sup>King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia; and <sup>2</sup>Endocrinology Associates, Phoenix, Arizona.

Address correspondence to Saleh A. Aldasouqi, MD, King Fahd Military Teaching Hospital, P.O. Box 9862, Jeddah 21159, Saudi Arabia. E-mail: [saldasouqi@pol.net](mailto:saldasouqi@pol.net).

© 2003 by the American Diabetes Association.



References

1. Faichney JD, Tate PW: Metformin in type 1 diabetes: is this a good or bad idea? (Letter). *Diabetes Care* 26:1655, 2003

2. Horlen C, Malone R, Bryant B, Dennis B, Carey T: Frequency of inappropriate metformin prescriptions (Letter). *JAMA* 287: 2504–2505, 2002
3. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA: Lactic acidosis in patients with diabetes treated with metformin (Letter). *N Engl J Med* 338:265–266, 1998
4. Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM: Metformin and thiazolidinedione use in Medicare patients with heart failure. *JAMA* 290:81–85, 2003
5. The American Association of Clinical Endocrinologists calls for patients with diabetes to take charge of their health [article online], 2002. Available from <http://www.aace.com/pub/press/releases/index.php?r=20020517>. Accessed 22 May 2002
6. Lalou JD, Lacroix C, Compagnon P, De Cagny B, Rigaud JP, Bleichner G, Chauveau P, Dulbecco P, Guerin C, Haegy JM, Loirat P, Marchand B, Rvaud Y, Weyne P, Fournier A: Role of metformin accumulation in metformin-associated lactic acidosis. *Diabetes Care* 18:779–784, 1995
7. Lalou JD, Race JM: Lactic acidosis in metformin therapy: searching for a link with metformin in reports of “metformin-associated lactic acidosis.” *Diabetes Obes Metab* 3:195–201, 2001
8. Rachmani R, Slavachevski I, Levi Z, Zadok BS, Kedar Y, Ravid M: Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. *European J Int Med* 13:428–433, 2002
9. Teale KF, Devine A, Stewart H, Harper NJ: The management of metformin overdose. *Anesthesia* 53:698–701, 1998
10. Jones GC, Macklin JP: Contraindications to the use of metformin: evidence suggests that it is time to amend the list. *BMJ* 326:4–5, 2000

## High Prevalence of Peripheral Arterial Disease but Low Antiplatelet Treatment Rates in Elderly Primary Care Patients With Diabetes

**A**lthough diabetes is primarily a metabolic disorder, it is also a vascular disease (1). We aimed to determine the prevalence of peripheral arterial dis-

ease (PAD), comorbidity of atherothrombotic manifestations, and antiplatelet treatment intensity among elderly diabetic patients in primary care, as previous studies usually investigated smaller and highly selected samples.

In this cross-sectional study, 344 general practitioners throughout Germany determined the ankle-brachial index (ABI) of 6,880 consecutive, unselected patients aged  $\geq 65$  years with bilateral Doppler ultrasound measurements (2). PAD was defined as ABI  $< 0.9$ , or peripheral revascularization, or amputation because of PAD. Additionally, the World Health Organization questionnaire on intermittent claudication was used to assess symptomatic PAD. Coronary artery disease (CAD) events (infarction or revascularization of coronary vessels) and cerebrovascular disease (CVD) events (stroke or revascularization of carotids) were taken from the patient’s history. Diabetes was defined according to the clinical diagnosis of the physician, and/or HbA<sub>1c</sub>  $\geq 6.5\%$ , and/or intake of oral antidiabetic medication, and/or application of insulin.

There were 1,743 patients classified as having diabetes; the median disease duration was 6 years (1st and 3rd quartile: 2, 11), median HbA<sub>1c</sub> 6.6% (5.9, 7.3), mean age  $72.5 \pm 5.4$  years, and 51.4% were women. Patients with diabetes had, in comparison with nondiabetic subjects, a higher prevalence of PAD, defined as ABI  $< 0.9$  (26.3 vs. 15.3%, univariate odds ratio [OR] 2.0 [95% CI: 1.7–2.3]), intermittent claudication (5.1 vs. 2.1%, OR 2.5 [1.9–3.4]), CAD events (16.1 vs. 10.6%, OR 1.6 [1.4–1.9]), and CVD events (6.8 vs. 4.8%, OR 1.4 [1.2–1.8]).

Only 57.4% of the diabetic patients with previously known PAD (as the only atherothrombotic manifestation) received antiplatelet therapy with aspirin, clopidogrel, or ticlopidine (which was similar to nondiabetic patients, 54.4%;  $P = 0.63$ ). If only CAD and/or CVD were present, the treatment rates were 75.1% for diabetic patients and 72.8% for nondiabetic patients ( $P = 0.51$ ), and if CAD and/or CVD were present in addition to PAD, rates were 81.8% for diabetic patients and 80.7% for nondiabetic patients ( $P = 0.87$ ).

Elderly patients with diabetes had an increased risk for PAD and CAD and CVD events compared with nondiabetic patients. However, the risk of PAD in dia-

betic subjects was substantially higher than for one of the other atherothrombotic manifestations. In terms of antiplatelet treatment, no difference was found between diabetic and nondiabetic patients. In addition, despite the well-established benefits of antiplatelet therapy in high-risk groups (3), patients with PAD were less intensively treated than patients with CAD. In accordance with current guidelines, efforts should be made to substantially intensify secondary prevention with antiplatelet therapy in patients with symptomatic or asymptomatic PAD (4).

STEFAN LANGE, MD<sup>1</sup>  
 CURT DIEHM, MD, PHD<sup>2</sup>  
 HARALD DARIUS, MD, PHD<sup>3</sup>  
 ROMAN HABERL, MD, PHD<sup>4</sup>  
 JENS RAINER ALLENBERG, MD, PHD<sup>5</sup>  
 DAVID PITTRÖW, MD<sup>6</sup>  
 ALEXANDER SCHUSTER, MD<sup>7</sup>  
 BERNDT VON STRITZKY, MD<sup>8</sup>  
 GERHART TEPOHL, MD<sup>9</sup>  
 HANS JOACHIM TRAMPISCH, PHD<sup>1</sup>

From the <sup>1</sup>Department of Medical Informatics, Biometry and Epidemiology, University of Bochum, Bochum, Germany; the <sup>2</sup>Department of Internal Medicine/Vascular Medicine, Affiliated Teaching Hospital, Ruprecht-Karls University of Heidelberg, Karlsbad-Langensteinbach, Germany; the <sup>3</sup>Medical Clinic I, Klinikum Berlin-Neukölln, Vivantes Netzwerk für Gesundheit, Berlin, Germany; the <sup>4</sup>Department of Neurology, Municipal Hospital München-Harlaching, Munich, Germany; the <sup>5</sup>Department of Surgery, Section for Vascular Surgery, Ruprecht-Karls University of Heidelberg, Heidelberg, Germany; the <sup>6</sup>Department of Clinical Pharmacology, Medical Faculty, Technical University of Dresden, Dresden, Germany; <sup>7</sup>3P Consulting, Pöcking, Germany; the <sup>8</sup>Medical Department, Sanofi-Synthelabo, Berlin, Germany; and the <sup>9</sup>Practice for Angiology, Munich, Germany.

Address correspondence to Dr. Stefan Lange, Abteilung für Medizinische Informatik, Biometrie und Epidemiologie, Ruhr-Universität Bochum, Universitätsstr. 150, D-44801 Bochum, Germany. E-mail: stefan.f.lange@ruhr-uni-bochum.de.

S.L. has received research support from Sanofi-Synthelabo. C.D., H.D., J.R.A., B.V.S., and H.J.T. are on the advisory panel of the getABI study group. H.D. and H.J.T. serve as advisors to Sanofi-Synthelabo. B.V.S. is on the board of directors of and holds stock in Sanofi-Synthelabo.

© 2003 by the American Diabetes Association.

### References

1. Deedwania P: Diabetes and vascular disease: common links in the emerging epidemic of coronary artery disease. *Am J Cardiol* 91:68–71, 2003
2. getABI Study Group. getABI: German Epidemiological Trial on Ankle Brachial In-

- dex for elderly patients in family practice to detect peripheral arterial disease, significant marker for high mortality. *VASA* 31:241–248, 2002
3. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 324: 71–86, 2002
  4. Dormandy J, Rutherford R, TASC Working Group: Management of peripheral arterial disease (PAD): TransAtlantic Inter-Society Consensus (TASC). *J Vasc Surg* 31:S1–S296, 2000

## Patient and Provider Congruence

Measures of effective diabetes management have traditionally included either provider adherence to best practice guidelines or clinical indicators such as laboratory values (1). This gives the clinical picture from the provider's viewpoint but leaves out the patient perspective. This descriptive study was designed to determine congruence between rural patient self-reported and provider-documented information on American Diabetes Association (ADA)-recommended guidelines for measurement and control of HbA<sub>1c</sub>, blood pressure, lipid levels, and preventive services (2,3).

Provider medical record information and patient questionnaires were matched for 149 patients, 45 years of age and with a diagnosis of type 2 diabetes, seen at four rural health care facilities between January 1999 and August 2000. There were significant differences ( $P < 0.05$ ) between patients' self-reports and providers in multiple areas. The aggregate percentage of patients with an HbA<sub>1c</sub> measurement was similar (57 vs. 54%) between provider documentation and patient self-report, respectively. When data were matched by individual, i.e., both patient and provider agree test was or was not done, HbA<sub>1c</sub> congruence was 47%, blood pressure measurement 79%, cholesterol check 60%, pneumovax 53%, influenza vaccination 44%, and eye examination 42%. A lack of congruence was evident in preventive services. Patients reported a significantly higher ( $P < 0.05$ ) percentage of influenza vaccinations (71 to 27%) and pneumovax rates (58 to 33%) when com-

pared with provider information. Medical records documented that 13% of patients had a dilated eye exam in the past year but 82% reported having one and named the ophthalmologist who performed it.

On chart review, 93% ( $n = 136$ ) of patients were on medication for diabetes management, but patients self-reported 81% ( $n = 110$ ). Thirty-six percent ( $n = 53$ ) of patients were on a lipid-lowering medication; 17 patients agreed, and 45% ( $n = 40$ ) of patients not on a documented lipid-lowering agent thought they were. Eighty-one percent ( $n = 72$ ) of patients with a diagnosis of hypertension were on a medication to lower their blood pressure, and 44 of these individuals (61%) agreed.

Diabetes requires a lifelong commitment to maintain control. To achieve this, providers must implement clinical practice guidelines into patient care. Patients must take an active role in their disease management. The results of this study indicate that these may not be happening in rural areas. There was suboptimal provider implementation of ADA recommended guidelines, limited patient knowledge about testing and medication use, and a disconnection between patient and provider for preventive services received. Diabetes is a complex metabolic disease in which the reasoning behind therapeutic goals can be difficult to understand. Changes in the traditional model of care that increase patient education and understanding of their disease while improving provider adherence to ADA guidelines are needed in rural areas.

KAREN ZULKOWSKI, DNS  
PATRICIA COON, MD  
CHARLES WITTNAM, MD

From the Center on Aging, Deaconess Billings Clinic, Billings, Montana; and the College of Nursing, Montana State University–Bozeman, Billings, Montana.

Address correspondence to Dr. Karen Zulkowski, Deaconess Billings Clinic, Center on Aging, P.O. Box 37000, Billings, MT 59107-9890. E-mail: karenz@montana.edu.

© 2003 by the American Diabetes Association.

**Acknowledgments**— This study was funded by Administration on Aging Grant no. 90-AM-2304.

We thank the Deaconess Billings Clinic Center on Aging, including Connie Koch, Karen Gransbery, Betty Mulette, and Brenda Hellyer.

## References

1. Johnson SB: Methodological issues in diabetes research: measuring adherence. *Diabetes Care* 15:1658–1667, 1992
2. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). *Diabetes Care* 22 (Suppl. 1):S32–S41, 1999
3. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). *Diabetes Care* 23 (Suppl. 1):S1–S22, 2000

## Maturity-Onset Diabetes of the Young (MODY) Mutation in Type 2 Diabetes and Latent Autoimmune Diabetes of the Adult

Owen et al. (1) reported etiologic heterogeneity among 268 subjects with type 2 diabetes, of whom ~10% had autoantibodies and ~1% had mutations in *HNF1A* (MODY3) encoding hepatic nuclear factor-1 $\alpha$ . We hypothesized that maturity-onset diabetes of the young (MODY) gene mutations would also be found in subjects with latent autoimmune diabetes of the adult (LADA) (2). We studied 37 Canadian subjects diagnosed with LADA (of whom 20 were female) and 54 control subjects with type 2 diabetes (of whom 28 were female). LADA was diagnosed when a type 2 diabetic patient concurrently had positive autoantibodies against GAD and/or the intracytoplasmic domain of tyrosine phosphatase-like protein, insulinoma-associated protein (IA)-2, using validated assays (sensitivity:specificity of 86:92% for anti-GAD and 64:86% for anti-IA-2, respectively [3,4]). Type 2 diabetic control subjects were negative for autoantibodies by the same assays. Using Student's *t* test (for means  $\pm$  SD of quantitative traits) or  $\chi^2$  analysis (for discrete traits), the LADA subjects were found to be younger ( $44.4 \pm 14.3$  vs.  $51.6 \pm 12.6$  years,  $P = 0.011$ ) and leaner (BMI  $28.7 \pm 6.5$  vs.  $32.8 \pm 6.7$  kg/m<sup>2</sup>,  $P = 0.005$ ), and despite a tendency toward shorter disease duration ( $24.8 \pm 23.8$  vs.  $34.8 \pm 27.7$  months,  $P = 0.07$ ), were more likely to



receive insulin (59.5 vs. 22.1%,  $P = 0.0003$ ) than type 2 diabetic control subjects. Because most MODY mutations occur within *HNF1A* (MODY3) or *GCK* (MODY2) encoding glucokinase (5), we then tested our hypothesis by sequencing the promoter, exons, and >100 nucleotides flanking each intron-exon boundary of *HNF1A* and *GCK* as described (6) from genomic DNA of all 91 subjects (>500 kilobases sequenced in total). No subject had a MODY3 mutation. However, each group had one heterozygote for the MODY2 *GCK* IVS3 -8G>A mutation (6), i.e., 2.7% of subjects in the LADA group versus 1.9% of type 2 diabetic control subjects ( $P = 0.65$ , NS). This mutation was absent in 250 nondiabetic control subjects. Thus, a small proportion of subjects with either LADA or type 2 diabetes can also have a MODY gene mutation.

JAMES MCKINNEY, BSC<sup>1</sup>  
HENIAN CAO, MD<sup>1</sup>  
MARGARET T. BEHME, PHD<sup>2</sup>  
JEFFREY L. MAHON, MD<sup>2</sup>  
ROBERT A. HEGELE, MD<sup>1</sup>

From the <sup>1</sup>Robarts Research Institute, London, Ontario, Canada; and the <sup>2</sup>Department of Medicine, Epidemiology, and Biostatistics, University of Western Ontario, London, Ontario, Canada.

Address correspondence to Robert A. Hegele, 100 Perth Dr., London, Ontario, Canada N6A5K8. E-mail: hegele@robarts.ca.

© 2003 by the American Diabetes Association.

## References

- Owen KR, Stride A, Ellard S, Hattersley AT: Etiological investigation of diabetes in young adults presenting with apparent type 2 diabetes. *Diabetes Care* 26:2088–2093, 2003
- Hosszafalusi N, Vatay A, Rajczy K, Prohaszka Z, Pozsonyi E, Horvath L, Grosz A, Gero L, Madacsy L, Romics L, Karadi I, Fust G, Panczel P: Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. *Diabetes Care* 26:452–457, 2003
- Behme MT, Mahon JL, Dupre J: Autoantibodies and HLA susceptibility markers in Canadian first-degree relatives of patients with type 1 diabetes. *Ann NY Acad Sci* 958:228–231, 2002
- Bingley PJ, Bonifacio E, Mueller PW: Diabetes Antibody Standardization Program: first assay proficiency evaluation. *Diabetes* 52:1128–1136, 2003
- Fajans SS, Bell GI, Polonsky KS: Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. *N Engl J Med* 345:971–980, 2001

6. Cao H, Shorey S, Robinson J, Metzger DL, Stewart L, Cummings E, Hegele RA: *GCK* and *HNF1A* mutations in Canadian families with maturity onset diabetes of the young (MODY). *Hum Mutat* 20:478–479, 2002

## It Can Be Done

*Editor's comment: After reading Dr. Hood's results in an abstract for the 2003 American Diabetes Association (ADA) meeting, I invited him to write this letter. It serves to remind clinicians caring for diabetic patients that it can be done and to stimulate us to keep trying and to not be satisfied with less than the ADA's evidence-based goals.*

The American Diabetes Association (ADA) has set standards of care that include various metabolic targets that are founded on evidenced-based medicine (1). Despite the widespread dissemination of these targets, many patients fail to obtain adequate control. There have been progressive developments in the understanding of type 2 diabetes and its attendant risk for both microvascular and macrovascular complications. With the host of new treatments available to the diabetes care team, the patient has an unprecedented opportunity to adequately control risk factors. Despite this exciting state of affairs, many clinicians are not of the opinion that these targets can routinely be met in clinical practice. One is hard pressed to find published data documenting success in achieving these goals. The purpose of this letter is to demonstrate that many of the goals espoused by the ADA may in fact be achievable in the majority of patients with type 2 diabetes.

The following is a cross-sectional study of the 452 active patients seen for type 2 diabetes in a community-based endocrine practice during the months of May through July 2003. These patients had their first visit at least 6 months prior and at least one other visit during the previous 6 months. Patients were referred for comprehensive diabetes education at the time of initial evaluation with follow-up education as needed. Data are reported as means  $\pm$  SD (range). The average age was  $64.9 \pm 13.9$  (11.4–92.4) years, and duration of diabetes was  $12.2 \pm 8.9$  (1.0–

51.0) years. Women represented 57.7%, Caucasians 83.4%, and African Americans 13.9%. The average BMI was  $34.1 \pm 8.1$  kg/m<sup>2</sup> (19.6–78.0), whereas waist circumference was  $42.3 \pm 6.6$  (27.0–65.3) inches in women and  $44.0 \pm 7.2$  (31.0–75.5) inches in men.

HbA<sub>1c</sub> was  $6.38 \pm 0.90\%$  (4.9–11.9) with 85.4% of subjects falling in the <7.0% range. The systolic blood pressure was  $124.0 \pm 15.0$  mmHg (80–210) with 75.4% of subjects falling in the  $\leq 130$ -mmHg range. Diastolic blood pressure was  $68.2 \pm 10.7$  mmHg (30–100) with 92.7% of subjects falling in the  $\leq 80$ -mmHg range. LDL cholesterol was  $81.2 \pm 25.0$  mg/dl (27.0–179.7) with 81.8% of subjects falling in the <100-mg/dl range. Triglycerides were  $158.3 \pm 129.0$  mg/dl (20–2,046) with 59.3% of subjects falling in the <150-mg/dl range. HDL cholesterol in women was  $54.0 \pm 14.5$  mg/dl (25.2–113.0) with 56.2% of subjects falling in the >50-mg/dl range. HDL cholesterol in men was  $45.0 \pm 11.4$  mg/dl (25.9–95.0) with 59.2% of subjects falling in the >40-mg/dl range. Antiplatelet therapy was prescribed to 94.2% of patients aged  $\geq 30$  years in whom such therapy was not contraindicated.

Goals that were readily attainable included antiplatelet therapy, LDL cholesterol, blood pressure, and HbA<sub>1c</sub>. More problematic goals included triglycerides and HDL cholesterol. Polypharmacy was common, with an average of  $5.1 \pm 2.0$  (0–11) medications being used to treat glucose, blood pressure, and lipids. The multiplicity of risk factors, the difficulty of long-term lifestyle changes, the complexity and cost of pharmacologic regimens, and the cost, time, and discomfort of self-monitoring of blood glucose all contribute to the difficulty in managing this condition. The fact remains, however, that many of these goals are readily attainable if all of the tools at our disposal are used in an aggressive and systematic fashion that blends science and clinical judgment. The clinician's belief in the importance of these goals and an implacable commitment to pursue them (with aggressive polypharmacy, if necessary) are essential.

ROBERT C. HOOD, MD, FRCP(C), FACE

From the Endocrine Clinic of Southeast Texas, Beaumont, Texas.

Address correspondence to Robert C. Hood, Endocrine Clinic of Southeast Texas, 3070 College #403, Beaumont, TX 77701. E-mail: setxendo@yahoo.com.

R.C.H. has received financial support for lecturing services from Novo Nordisk, Takeda, GlaxoSmithKline, Aventis, Merck, Pfizer, Wyeth, and Novartis and has received research support from Pfizer.

© 2003 by the American Diabetes Association.

## References

1. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). *Diabetes Care* 26 (Suppl. 1):S33–S50, 2003

## COMMENTS AND RESPONSES

### Glimepiride and Serum Adiponectin Level in Type 2 Diabetic Subjects

Response to Nagasaka et al.

We read with interest the article by Nagasaka et al. (1) reporting that glimepiride, a new agent of sulfonylurea, has an increasing effect on circulating adiponectin concentration, which may play a role in mediating insulin sensitivity. The authors demonstrated that serum adiponectin concentration increased significantly from  $22.1 \pm 2.7$  to  $28.5 \pm 2.8 \mu\text{g/ml}$  after 3 months' glimepiride treatment. However, their baseline level of serum adiponectin was markedly higher than that of the Japanese type 2 diabetic subjects reported by Tsunekawa et al. (2) ( $22.1 \pm 2.7$  vs.  $6.61 \pm 3.06 \mu\text{g/ml}$ ) in spite of higher BMI ( $26.5 \pm 0.9$  vs.  $21.2 \pm 2.2 \text{ kg/m}^2$ ) and greater homeostasis model assessment of insulin resistance ( $5.0 \pm 0.8$  vs.  $2.54 \pm 2.25$ ), although both groups measured serum adiponectin levels with Linco radioimmunoassay kits (St. Charles, MO).

Recently, Hara et al. (3) reported the association between single nucleotide polymorphism (SNP) 276 of the adiponectin gene and plasma adiponectin levels, showing that the G allele at position 276 was linearly associated with

lower plasma adiponectin levels (G/G:  $10.4 \pm 0.85 \mu\text{g/ml}$ ; G/T:  $13.7 \pm 0.87 \mu\text{g/ml}$ ; and T/T:  $16.6 \pm 2.24 \mu\text{g/ml}$ ) in Japanese subjects with higher BMIs. Here, we measured serum adiponectin concentrations by human adiponectin enzyme-linked immunosorbent assay kits (Otsuka Pharmaceutical, Tokyo, Japan) in Japanese diabetic patients and investigated the influence of SNP 276 of the adiponectin gene. A total of 101 type 2 diabetic subjects (70 men and 31 women, aged  $55.5 \pm 8.7$  years) were studied (data are means  $\pm$  SD). Twenty-eight subjects (20 men and 8 women, aged  $55.2 \pm 6.5$  years) had been treated with glimepiride (daily dosage  $1.5 \pm 0.6 \text{ mg}$ ) and 31 subjects (22 men and 9 women, aged  $60.2 \pm 6.3$  years) with gliclazide (daily dosage  $39.3 \pm 18.4 \text{ mg}$ ) for  $>6$  months. The remaining 42 subjects (28 men and 14 women, aged  $51.4 \pm 10.3$  years) had been treated with diet therapy alone and without any hypoglycemic agents. BMI (glimepiride group:  $24.6 \pm 3.4 \text{ kg/m}^2$ ; gliclazide group:  $24.3 \pm 3.1$ ; and diet group:  $24.5 \pm 5.3$ ), HbA<sub>1c</sub> (glimepiride group:  $7.2 \pm 1.2\%$ ; gliclazide group:  $6.7 \pm 0.5$ ; and diet group:  $6.8 \pm 1.4$ ), homeostasis model assessment of insulin resistance (glimepiride group:  $3.3 \pm 2.3$ ; gliclazide group:  $2.5 \pm 1.4$ ; and diet group:  $3.1 \pm 2.0$ ), and serum lipid levels (data not shown) were not significantly different among the groups. Serum adiponectin levels in subjects with glimepiride ( $5.34 \pm 2.82 \mu\text{g/ml}$ ) and gliclazide ( $5.38 \pm 2.61 \mu\text{g/ml}$ ) were significantly lower than that of the diet group ( $7.31 \pm 4.87 \mu\text{g/ml}$ ). The G allele frequency of SNP 276 of the adiponectin gene was 0.70. The serum adiponectin levels were not different among the genotypes at position 276 of the adiponectin gene (G/G,  $n = 54$  [53.5%]:  $6.43 \pm 5.54 \mu\text{g/ml}$ ; G/T,  $n = 34$  [33.7%]:  $6.31 \pm 4.25 \mu\text{g/ml}$ ; and T/T,  $n = 13$  [12.8%]:  $5.70 \pm 2.00 \mu\text{g/ml}$ ). After various treatments were started, SNP 276 of the adiponectin gene did not associate with significantly different serum adiponectin levels.

Again, the serum adiponectin levels after glimepiride therapy reported by Nagasaka et al. (1) were quite higher than our results. Although cautious interpretation of our results is necessary because the present study is cross-sectional and the number of subjects is small, multiple factors such as glycemic control per se, obesity (4), polymorphisms of the adi-

ponectin gene (3), or peroxisome proliferator-activated receptor- $\gamma$ 2 gene (5) may affect serum adiponectin concentration. In addition, therapy with sulfonylureas, such as glimepiride (1) and gliclazide, is a possible affecting factor for serum adiponectin level. Prospective and large-scale studies are needed to clarify the interactions between environmental factors or therapeutic interventions and genetic factors on serum adiponectin concentrations.

KEIJI YOSHIOKA, MD<sup>1</sup>  
TOSHIHIDE YOSHIDA, MD<sup>2</sup>  
TOSHIKAZU YOSHIKAWA, MD<sup>3</sup>

From the <sup>1</sup>Department of Diabetes and Endocrinology, Matsushita Memorial Hospital, Moriguchi, Japan; the <sup>2</sup>Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto; and the <sup>3</sup>Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Address correspondence to Keiji Yoshioka, MD, Department of Diabetes and Endocrinology, Matsushita Memorial Hospital, 5-55, Sotojima-cho, Moriguchi, Osaka 570-8540, Japan. E-mail: yoshik@mue.biglobe.ne.jp.

© 2003 by the American Diabetes Association.

**Acknowledgments**— This work was supported by a Grant-in-Aid for Scientific Research (no. 14571106) (to T. Yoshida) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

## References

1. Nagasaka S, Taniguchi A, Aiso Y, Yatagai T, Nakamura T, Nakai Y, Fukushima M, Kuroe A, Ishibashi S: Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes (Letter). *Diabetes Care* 26:2215–2216, 2003
2. Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hara H, Kano H, Fukatsu A, Nomura N, Miyazaki A, Iguchi A: Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. *Diabetes Care* 26:285–289, 2003
3. Hara K, Boutin P, Mori Y, Tobe K, Dian C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, Kadowaki H, Hagura R, Akanuma Y, Yazaki Y, Nagai R, Taniyama M, Matsubara K, Yoda M, Nakano Y, Kimura S, Tomita M, Kimura S, Ito C, Froguel P, Kadowaki T: Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. *Diabetes* 51:536–540, 2002
4. Stefan N, Stumvoll M: Adiponectin: its

role in metabolism and beyond. *Horm Metab Res* 34:469–474, 2002

5. Yamamoto Y, Hirose H, Miyashita K, Nishikai K, Saito I, Taniyama M, Tomita M, Saruta T: PPAR  $\gamma$  2 gene Pro12Ala polymorphism may influence serum level of an adipocytes-derived protein, adiponectin, in the Japanese population. *Metabolism* 51:1407–1409, 2002

## Glimepiride and Serum Adiponectin Level in Type 2 Diabetic Subjects

Response to Yoshioka, Yoshida, and Yoshikawa

We thank Yoshioka, Yoshida, and Yoshikawa for their comments on our article (1) in this issue of *Diabetes Care* (2). We reported that serum adiponectin concentration increased after 3 months' glimepiride treatment in type 2 diabetic patients (1). They indicated that baseline values of serum adiponectin ( $22.1 \pm 2.7 \mu\text{g/ml}$ , mean  $\pm$  SE) seem to be higher than those expected from subjects with greater BMI ( $26.5 \pm 0.9 \text{ kg/m}^2$ ) and homeostasis model assessment of insulin resistance ( $5.0 \pm 0.8$ ) levels. First, we must apologize for not having corrected the final results of serum adiponectin concentration by using the ratio of sample dilution. The correct results of our study (1) are as follows: serum adiponectin concentration increased from  $11.1 \pm 1.3$  to  $14.2 \pm 1.4 \mu\text{g/ml}$  (29%,  $P = 0.015$  by Wilcoxon's sign-rank test) in the glimepiride-treated patients ( $n = 28$ ), and the concentration also increased from  $9.4 \pm 1.5$  to  $10.3 \pm 1.7 \mu\text{g/ml}$  (10%,  $P = 0.034$ ) by metformin treatment in another group of type 2 diabetic patients ( $n = 12$ ) matched with the glimepiride group for sex, age, BMI, glycemia, and insulinemia. Statistical analysis and data interpretation remained unchanged despite the changes in absolute values of serum adiponectin concentration.

Along with glimepiride (1,3), insulin-sensitizing thiazolidinediones are known to increase mRNA and circulating levels of adiponectin (4,5). We have also confirmed that serum adiponectin concentration increased from  $9.1 \pm 2.3$  to  $19.6 \pm 2.0 \mu\text{g/ml}$  (123%,  $P < 0.001$ ) in 15 type 2

diabetic patients (10 men and 5 women, aged  $61 \pm 2$  years, BMI  $27.2 \pm 0.4 \text{ kg/m}^2$ ) after 4 months' pioglitazone treatment, which was concomitant with improvements in fasting glucose from  $161 \pm 6$  to  $137 \pm 6 \text{ mg/dl}$  ( $P = 0.023$ ), HbA<sub>1c</sub> from  $7.9 \pm 0.2$  to  $7.2 \pm 0.2\%$  ( $P = 0.002$ ), and homeostasis model of insulin resistance from  $5.9 \pm 3.0$  to  $3.8 \pm 0.4$  ( $P = 0.025$ ). Very recently, blockade of the renin-angiotensin system was also shown to increase serum adiponectin concentration (15% by temocapril and 30% by candesartan, respectively) as well as insulin sensitivity in hypertensive men (6). Therefore, at least three kinds of therapeutic interventions are known to increase both adiponectinemia and insulin sensitivity in men. The mechanisms responsible for increased adiponectinemia by glimepiride and blockade of the renin-angiotensin system await further investigation. In addition, we agree with Yoshioka, Yoshida, and Yoshikawa in that further clinical study is also necessary to establish the long-term beneficial effects of such pharmacological interventions to increase adiponectinemia in type 2 diabetic patients.

SHOICHIRO NAGASAKA, MD<sup>1</sup>  
 ATARU TANIGUCHI, MD<sup>2</sup>  
 YOSHITAKA AISO, MD<sup>3</sup>  
 TOSHIMITSU YATAGAI, MD<sup>1</sup>  
 TOMOATSU NAKAMURA, MD<sup>1</sup>  
 YOSHIKATSU NAKAI, MD<sup>4</sup>  
 MITSUO FUKUSHIMA, MD<sup>5</sup>  
 AKIRA KUROE, MD<sup>2</sup>  
 SHUN ISHIBASHI, MD<sup>1</sup>

From the <sup>1</sup>Division of Endocrinology and Metabolism, Jichi Medical School, Tochigi, Japan; the <sup>2</sup>Division of Diabetes, Kansai-Denryoku Hospital, Osaka, Japan; the <sup>3</sup>Aiso Clinic, Tokyo, Japan; the <sup>4</sup>College of Medical Technology, Kyoto University, Kyoto, Japan; and the <sup>5</sup>Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Address correspondence to Shoichiro Nagasaka, MD, Division of Endocrinology and Metabolism, Jichi Medical School, Yakushiji 3311-1, Minami-kawachi, Tochigi 329-0498, Japan. E-mail: sngsk@jichi.ac.jp.

© 2003 by the American Diabetes Association.

### References

1. Nagasaka S, Taniguchi A, Aiso Y, Yatagai T, Nakamura T, Nakai Y, Fukushima M, Kuroe A, Ishibashi S: Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes (Letter). *Diabetes Care* 26:2215–2216, 2003

2. Yoshioka K, Yoshida T, Yoshikawa T: Glimepiride and serum adiponectin level in type 2 diabetic subjects (Letter). *Diabetes Care* 26:3360–3361, 2003
3. Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hirai H, Kano H, Fukatsu A, Nomura N, Miyazaki A, Iguchi A: Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic patients. *Diabetes Care* 26:285–289, 2003
4. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPAR $\gamma$  ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. *Diabetes* 50:2094–2099, 2001
5. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I: Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. *Diabetes* 52:1655–1663, 2003
6. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. *Hypertension* 42:76–81, 2003

## Comparison of Repaglinide and Nateglinide in Combination With Metformin

Response to Raskin et al.

I believe there are significant limitations in the study by Raskin et al. (1) in the June issue of *Diabetes Care* that preclude broad conclusions about the relative efficacy of nateglinide and repaglinide. They presented the results of a "head-to-head assessment of the relative efficacy and safety of repaglinide versus nateglinide, under conditions of combination therapy with metformin."

The authors concluded that when both agents were compared in combination with metformin, repaglinide lowered fasting plasma glucose and HbA<sub>1c</sub> significantly better than nateglinide and with a similar safety profile. The design of the study precludes drawing conclusions about the comparable efficacy of these

agents. Patients were titrated to 2 g/day of metformin (if they were currently taking metformin) or switched from either a sulfonylurea or Glucovance to metformin, which was titrated to 2 g/day. Titration to the final metformin dose occurred over 4 weeks, at which point either repaglinide or nateglinide was added.

Combination therapy is usually initiated as either first-line therapy in drug-naïve patients or added to stable doses of current therapy if glycemic goals are not met. This study was neither a head-to-head comparison of initial combination therapy with repaglinide/metformin versus nateglinide/metformin nor a true comparison of repaglinide and nateglinide added to metformin. In order to compare the efficacy of these agents as add-on therapy to metformin over a 16-week period, patients should have been maintained on the final dose of metformin for a sufficient period to allow their glycemic control to stabilize and establish a clear baseline.

The most important limitation of the study is that the nateglinide/metformin treatment arm was biased by including patients recently treated with sulfonylureas. The nateglinide label states that patients should not be switched from a sulfonylurea to nateglinide. Over one-third (33 of 96) of patients receiving the nateglinide/metformin combination had been on sulfonylurea monotherapy or Glucovance before being switched to the combination and were therefore treated outside of product labeling.

In addition, the underlying assumptions and relevant background information whereby the imputation method was chosen to handle missing data are not provided. Imputation is generally considered exploratory in nature, whereas the last observation carried forward approach is conservative and appropriate when reductions in the parameter under consideration reflect the improvement of disease.

Finally, the authors conclude that repaglinide achieved improved glycemic control with no difference in safety compared with nateglinide; however, there was a 3.5-fold increase in the incidence of hypoglycemia with repaglinide compared with nateglinide.

We believe that for the appropriate patient, nateglinide is a valuable treatment option to control postmeal glucose and reduce HbA<sub>1c</sub> and trust that physi-

cians will continue to exercise discretion in evaluating product comparisons before making clinical decisions.

MICHELLE A. BARON, MD

From the Department of U.S. Clinical Development and Medical Affairs, Novartis Pharmaceuticals, East Hanover, New Jersey.

Address correspondence to Michelle A. Baron, MD, Novartis Pharmaceuticals, One Health Plaza, 502/336, East Hanover, NJ 07960. E-mail: michelle.baron@pharma.novartis.com.

M.A.B. holds stock in Novartis Pharmaceuticals, Pfizer, and Johnson & Johnson.

© 2003 by the American Diabetes Association.

References

1. Raskin P, Klaff L, McGill S, South SA, Hollander P, Khutoryansky N, Hale PM: Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. *Diabetes Care* 26: 2063–2068, 2003

## Comparison of Repaglinide and Nateglinide in Combination With Metformin

### Response to Baron

We have seen Baron's letter in this issue of *Diabetes Care* (1) regarding our recent clinical research trial (2) and wish to point out the following facts for readers.

Regarding the matter of whether sufficient time was allowed to develop a response to metformin therapy, the duration of metformin treatment in this trial reached 20 weeks, which is more than enough time for metformin effects to stabilize. As shown in Fig. 1B of the arti-

cle, fasting plasma glucose values showed little or no change for either therapy group in the times from 4 to 16 weeks of therapy. The final fasting plasma glucose values achieved during repaglinide/metformin or nateglinide/metformin therapy were clearly different, and HbA<sub>1c</sub> values reflected this difference.

The issue of the possible effects of prior treatment is a consideration that is not unique to our study. This is precisely what the randomization procedure was intended to address. Statistical testing for imbalance between the treatment groups for previous oral antidiabetic drug therapy yielded a *P* value of 0.86 (any imbalances were insignificant).

Regarding concerns that a subset of patients previously treated with a sulfonylurea may have been unresponsive to nateglinide/metformin therapy, combination therapy enrollment of a patient population entirely lacking previous sulfonylurea therapy would be a doubtful reflection of clinical practice reality. When patients from this clinical trial were analyzed based on prior therapy, repaglinide/metformin produced significantly greater reductions of HbA<sub>1c</sub> values than nateglinide/metformin for patients who had previously received metformin, as well as for those who had previously received sulfonylureas (including Glucovance). The comparison of Table 1 makes it clear that the overall study conclusions were not solely determined by the nateglinide/metformin response of patients previously treated with sulfonylureas. While patients having prior sulfonylurea therapy had a lesser response to nateglinide/metformin than those previously treated with metformin, the majority of enrolled patients in this study had received prior metformin therapy. Both patient subsets showed significant HbA<sub>1c</sub> reductions from baseline for both treatment regi-

Table 1—Change in HbA<sub>1c</sub> values by prior therapy

Previous therapy subset	Repaglinide/ metformin		Nateglinide/ metformin		<i>P</i> (repag/met vs. nateg/met)
	<i>n</i>	Change in HbA <sub>1c</sub> from baseline	<i>n</i>	Change in HbA <sub>1c</sub> from baseline	
Total study population	92	−1.28 (0.1)	89	−0.67 (0.1)	<0.001
Prior metformin	56	−1.29 (0.16)	60	−0.77 (0.11)	0.002
Prior sulfonylurea or glucovance	36	−1.27 (0.16)	29	−0.47 (0.19)	0.006

Date are means ± SE.

mens, and differences between repaglinide/metformin and nateglinide/metformin were significant for both patient subsets.

It is noteworthy that another direct comparison of repaglinide and nateglinide, under monotherapy conditions in patients who had received only diet and exercise for the previous 3 months, has reported similar differences in the efficacy of the two drugs (~0.5% difference in HbA<sub>1c</sub> changes in 16 weeks) (3).

Regarding the use of the incremental mean imputation statistical method of imputing missing values, it has been statistically demonstrated to be more accurate than the last observation carried forward method (4), so we implemented the incremental mean imputation method. The reader should be aware that the last observation carried forward method is also merely a method of imputing missing values, and in the case of the reported study, the last observation carried forward calculation method produced similar results: final reductions of HbA<sub>1c</sub> or fasting plasma glucose values from baseline were significantly greater for repaglinide/metformin therapy, by 0.63% and 19 mg/dl, respectively.

Finally, the incidence of minor hypoglycemic events (seven patients for repaglinide/metformin and two for nateglinide/metformin) clearly falls into the realm of a comparison of small numbers that are hazardous to declare statistically different, much less declare different by a specific factor (3.5-fold, etc.).

We appreciate the opportunity to clarify these issues.

PHILIP RASKIN, MD

From the Department of Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas.

Address correspondence to Dr. Philip Raskin, The University of Texas, Southwestern Medical Center at Dallas, Dept. of Internal Medicine, 5323 Harry Hines Blvd., Dallas, TX 75235-8858. E-mail: philip.raskin@utsouthwestern.edu.

P.R. has served on an advisory panel for, has received consulting fees from, and has received grant/research support from Novo Nordisk.

© 2003 by the American Diabetes Association.

References

1. Baron M: Comparison of repaglinide and nateglinide in combination with metformin (Letter). *Diabetes Care* 26:3361-3362, 2003
2. Raskin P, Klaff L, McGill S, South SA, Hollander P, Khutoryansky N, Hale PM: Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. *Diabetes Care* 26:2063-2068, 2003

3. Saad MF, Rosenstock J, Hale P, Khutoryansky N: Repaglinide vs. nateglinide monotherapy: a randomized, multicenter, open-label study (Abstract 44). *Endocrine Pract* 9 (Suppl. 1):17, 2003
4. Khutoryansky NM, Huang WC: Imputation techniques using SAS software for incomplete data in diabetes clinical trials. In *Pharmaceutical Industry SAS Users Group Conference Proceedings, Boston, MA, 2001*. Boston, MA, Pharmaceutical Industry SAS Users Group, p. 334-337

## Meta-Analysis of Low-Glycemic Index Diets in the Management of Diabetes

### Response to Franz

In the editorial by Franz (1) on the value of low-glycemic index diets, the results of our meta-analysis, which were published in the same issue of *Diabetes Care* (2), have been misinterpreted and therefore misrepresented. Specifically, the author contrasts the overall decrease in HbA<sub>1c</sub> of ~1-2% seen with various nutrition interventions with a reduction of 0.43% from low-glycemic index diets. The 0.43% reduction, however, is not the overall effect of a low-glycemic index diet, but the incremental effect of a low-glycemic index diet over and above that seen with an equally intensive nutrition intervention. Thus if a nutrition intervention improves HbA<sub>1c</sub> by 1%, then the meta-analysis predicts that a low-glycemic index version of that intervention will result in an overall reduction of 1.43%.

In the reviews and studies cited by Franz, the change in HbA<sub>1c</sub> levels of a nutrition intervention is compared with either a control group given a "basic" or "usual" level of care or with the baseline HbA<sub>1c</sub>. For example, in the Dose Adjustment For Normal Eating (DAFNE) study (3), the control group consisted of patients who simply continued to receive usual care for 6 months versus a group who received training in flexible intensive insulin treatment combining dietary

freedom and insulin adjustment. Similarly, in discussing the U.K. Prospective Diabetes Study (4), Franz compares the glycemic control at baseline with that after 3 months of intensive dietary intervention. In both of these instances, intensive nutritional interventions are compared with basic care. In the meta-analysis, however, we included only studies in which two equally intensive nutrition interventions were compared.

The author goes on to state that the 0.43% reduction in HbA<sub>1c</sub> is equivalent to a 7.4% reduction. This is incorrect. A 7.4% reduction in glycated proteins, as shown in the combined analysis with both fructosamine and HbA<sub>1c</sub> data, is larger and equivalent to >0.6% HbA<sub>1c</sub> in an individual with an HbA<sub>1c</sub> >8%. This is addressed in our discussion (2).

Lastly, the author states that the meta-analysis found that "in subjects with type 1 diabetes, HbA<sub>1c</sub> was reduced by ~0.4% units and in type 2 diabetes by ~0.2% units." This is also incorrect; we did not perform a subgroup analysis of HbA<sub>1c</sub> in type 1 versus type 2 diabetic subjects because there were insufficient data. However, we reported that the incremental reduction in glycated proteins was ~10% (equivalent to 0.8% HbA<sub>1c</sub>) in type 1 diabetic subjects and ~6% (equivalent to ~0.5% HbA<sub>1c</sub>) in type 2 diabetic patients.

The editorial's title, "The Glycemic Index: Not the Most Effective Nutrition Therapy Intervention," thus represents a misinterpretation of the results of the meta-analysis. It may, unfortunately, lead readers to dismiss the study's findings and potential value.

JENNIE C. BRAND-MILLER, PHD<sup>1</sup>  
 PETER PETOCZ, PHD<sup>2</sup>  
 STEPHEN COLAGIURI, MD<sup>3</sup>

From the <sup>1</sup>School of Molecular and Microbial Biosciences, University of Sydney, Sydney, Australia; the <sup>2</sup>Department of Mathematical Sciences, University of Technology, Sydney, Australia; and the <sup>3</sup>Department of Endocrinology, Diabetes, and Metabolism, Prince of Wales Hospital, Sydney, Australia.

Address correspondence to Jennie C. Brand-Miller, Human Nutrition Unit, University of Sydney, Sydney, NSW 2006, Australia. E-mail: j.brandmiller@mmb.usyd.edu.au.

J.C.B.-M. is the director of GI Limited and of the Sydney University Glycemic Index Research Service (SUGiRS) and has received honoraria for speaking engagements on the glycemic index of foods.

© 2003 by the American Diabetes Association.

.....

#### References

1. Franz MJ: The glycemic index: not the most effective nutrition therapy intervention (Editorial). *Diabetes Care* 26:2466–2468, 2003
2. Brand-Miller J, Hayne S, Petocz P, Colagiuri S: Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. *Diabetes Care* 26:2261–2267, 2003
3. DAFNE Study Group: Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: Dose Adjustment For Normal Eating (DAFNE) randomised controlled trial. *BMJ* 325:746–752, 2002
4. UK Prospective Diabetes Study Group: Response of fasting plasma glucose to diet therapy in newly presenting type II diabetic subjects (UKPDS 7). *Metabolism* 39:905–912, 1990

## Meta-Analysis of Low-Glycemic Index Diets in the Management of Diabetes

### Response to Franz

In her editorial (1) accompanying the meta-analysis carried out by Brand-Miller et al. (2), Dr. Franz describes the glycemic index as “not the most effective nutrition therapy intervention.” Her conclusion appears principally based on the fact that the reduction in HbA<sub>1c</sub> by 0.4–0.6% units (a 7.4% decrease in glycated protein is equivalent to ~0.6% HbA<sub>1c</sub> units) when comparing high- and low-glycemic index diets is less than that seen when considering other dietary manipulations, which may achieve decreases in HbA<sub>1c</sub> of 1–2% units (a 15–22% decrease in HbA<sub>1c</sub>). Franz appears to have missed a pivotal issue clearly discussed by Brand-Miller et al. in their article (2). The observed improvement in glycemic control is the net improvement over and above that of standard current best practice nutrition therapy (and medication) in the institutions where the studies were conducted. By failing to acknowledge the additional benefit that may be achieved by the choice of low-glycemic index foods and emphasizing only the importance of total carbohydrate, the American

Diabetes Association may be depriving people with diabetes of the full benefit of nutrition therapy. It is noteworthy that the recommendations of the Nutrition Study Group of the European Association for the Study of Diabetes (3) and the Food and Agriculture Organization/World Health Organization Expert Consultation on Carbohydrates (4) include advice to use the glycemic index as a means of determining the most appropriate choices of carbohydrate-containing foods.

JIM MANN, CNZM, DM, PHD, FRACP, FRSNZ

From the Nutrition Department, University of Otago, Dunedin, New Zealand.

Address correspondence to James I. Mann, Nutrition Department, University of Otago, P.O. Box 56, Science II Building, Union Street, Room 7N8, Dunedin, New Zealand. E-mail: beth.gray@stonebow.otago.ac.nz.

© 2003 by the American Diabetes Association.

.....

#### References

1. Franz MJ: The glycemic index: not the most effective nutrition therapy intervention (Editorial). *Diabetes Care* 26:2466–2468, 2003
2. Brand-Miller J, Hayne S, Petocz P, Colagiuri S: Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. *Diabetes Care* 26:2261–2267, 2003
3. Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD): Nutritional recommendations for the nutritional management of patients with diabetes mellitus. *Eur J Clin Nutri* 54:353–355, 2000
4. Food and Agriculture Organization/World Health Organization: *Carbohydrates in Human Nutrition: Report of a Joint FAO/WHO Expert Consultation*. FAO Food and Nutrition, 1998, p. 140 (Paper 66)

## Meta-Analysis of Low-Glycemic Index Diets in the Management of Diabetes

### Response to Brand-Miller et al. and Mann

Mann (1) and Brand-Miller et al. (2) state in this issue of *Diabetes Care* that study subjects have been on previous nutrition therapies before the implementation of low- versus high-

glycemic index diets. Although this may be the case, in reviewing the studies included in the meta-analysis, only two studies state this clearly. The first is the study by Fontvieille et al. (3), in which the low- compared with high-glycemic index diet did not improve HbA<sub>1c</sub> levels over 5 weeks but did result in a decrease in fructosamine ( $P < 0.05$ ). The second is the study by Heilbronn et al. (4), wherein subjects participated in 12 weeks of energy restriction. After 4 weeks on a weight loss diet similar in composition to the average Australian diet, the subjects were randomized to a low- versus high-glycemic index diet for 8 weeks. At week 12 there was no statistically significant difference in improving glycemic control or weight loss between the low- and high-glycemic index groups. However, if subjects in the reported trials had been on previous food/meal planning approaches, it supports the position of the American Diabetes Association, which holds that there is not evidence “to recommend use of low-glycemic index diets as a primary strategy in food/meal planning,” (5) but as is suggested in the editorial, “glycemic responses of foods can best be used for fine-tuning glycemic control” (6).

There are three questions that need answering in order to assist clinicians in deciding on an intervention approach. First, have two different approaches been compared and which approach has the better outcome? This is the question that Brand-Miller et al. addressed in their meta-analysis (7). They determined that low-glycemic index diets compared with high-glycemic index diets resulted in a small but significant improvement in glycemia (7.4% reduction in glycated proteins). Although Brand-Miller et al. (2) state in their letter that the change in HbA<sub>1c</sub> is  $>0.6\%$ , they also state in their conclusion that “after an average duration of 10 weeks, subjects who were following low-glycemic index diets had HbA<sub>1c</sub> levels ~0.4% lower than those ingesting a high-glycemic index diet.” But regardless if it is 0.4 or 0.6%, it is still less than other nutrition intervention outcomes cited in the editorial, which report decreases in HbA<sub>1c</sub> of ~1–2% and, therefore, are better choices for primary nutrition therapy interventions (8,9).

The second question is of equal importance. What is the expected outcome from the intervention? Table 1 lists the studies included in the meta-analysis with

**Table 1—Changes in HbA<sub>1c</sub> from baseline to study end from low- and high-glycemic index diets**

Reference, number of subjects (n), and study length	Baseline HbA <sub>1c</sub> : low- vs. high-GI diet	Study end HbA <sub>1c</sub> : low- vs. high-GI diet	HbA <sub>1c</sub> changes from baseline with the implementation of the low-GI diet
Heilbronn et al. (4), n = 45, 4 wks on weight loss diet followed by 8 weeks on weight loss diets of low or high GI	6.7%, after 4 wks of weight loss diets: 6.65 vs. 6.35%	6.04 vs. 6.06%	After implementation of the GI diets, a 0.6% decrease in low GI, not significantly different than high-GI diet; no difference in weight loss from low- vs. high-GI diets
Gilbertson et al. (10), n = 104, 52 weeks	8.3 vs. 8.6%	8.0 vs. 8.6%	0.3% decrease in low-GI group, although reported GIs were the same in both groups at study end
Giacco et al. (11), n = 63, 24 weeks	8.8 vs. 8.8%	8.6% (compliant group) vs. 9.1%	0.2% decrease in low-GI compliant group
Brand et al. (12), n = 16, 12 weeks	7.7 vs. 7.7%	7.0 vs. 7.9%	0.7% decrease in low-GI group
Collier, et al. (12), n = 7, 6 weeks	10.0 vs. 9.9%	10.0 vs. 9.86%	No difference at study end

GI, glycemic index.

a duration of 6 weeks or longer, their baseline HbA<sub>1c</sub> values, and the study-end HbA<sub>1c</sub> value. The low-glycemic index intervention resulted in decreases from baseline to study end in HbA<sub>1c</sub> ranging from 0.0 to 0.7%, with an average per subject decrease of 0.35%. Readers can decide the clinical significance of this change for themselves.

The final question is also of importance to clinicians. Can people with diabetes implement the intervention outside of a research center? Although not addressed in these studies, one clue does emerge from the reported research. In the longest study (10), which was 1 year, at the end of the year both groups reported diets with similar glycemic index values, suggesting that it may be difficult in the real world to change the overall glycemic index of an individual's food intake over the long term.

The bottom line is that dietitians and other health care providers will make the decision on which food/meal-planning approach their patients with diabetes will understand, be able to implement, and benefit from. Some individuals will benefit from simple guidelines as to what to eat and when, others will benefit from carbohydrate counting or exchange lists, moderate weight loss, and yes, some may even benefit from the use of low-glycemic index foods. However, the research suggests that the use of low-glycemic index diets is not as effective as other nutrition interventions. And ultimately, people with diabetes will decide what foods they

eat and, by using their glucose monitoring results, determine if their choices have led to their target goals.

MARION J. FRANZ, MS, RD, CDE

From Nutrition Concepts by Franz, Minneapolis, Minnesota.

Address correspondence to Marion J. Franz, MS, RD, CDE, Nutrition Concepts by Franz, Inc., 6635 Limerick Dr., Minneapolis, MN 55439. E-mail: marionfranz@aol.com.

© 2003 by the American Diabetes Association.



#### References

- Mann J: Meta-analysis of low-glycemic index diets in the management of diabetes (Letter). *Diabetes Care* 26:3364, 2003
- Brand-Miller JC, Petocz P, Colagiuri S: Meta-analysis of low-glycemic index diets in the management of diabetes (Letter). *Diabetes Care* 26:3363, 2003
- Fontvieille AM, Rizkalla SW, Penfornis A, Acosta M, Bornet FRJ, Slama G: The use of low glycaemic index foods improves metabolic control of diabetic patients over five weeks. *Diabet Med* 9:444–450, 1992
- Heilbronn LK, Noakes M, Clifton PM: The effect of high- and low-glycemic index energy restricted diets on plasma lipid and glucose profiles in type 2 diabetic subjects with varying glycemic control. *J Am Coll Nutr* 21:120–127, 2002
- American Diabetes Association: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Position Statement). *Diabetes Care* 26 (Suppl. 1):S51–S61, 2003
- Franz MJ: The glycemic index: not the most effective nutrition therapy intervention (Editorial). *Diabetes Care* 26:2466–2468, 2003
- Brand-Miller J, Hayne S, Petocz P, Colagiuri S: Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. *Diabetes Care* 26:2261–2267, 2003
- Pastors JG, Warshaw H, Daly A, Franz M, Kulkarni K: The evidence for the effectiveness of medical nutrition therapy in diabetes management. *Diabetes Care* 25: bp608–613, 2002
- Pastors JG, Franz MJ, Warshaw H, Daly A, Arnold L: How effective is medical nutrition therapy in diabetes care? *J Am Diet Assoc* 103:827–831, 2003
- Gilbertson HR, Brand-Miller JC, Thorburn AW, Evans E, Chondros P, Werther GA: The effect of flexible low glycemic index dietary advice versus measured carbohydrate exchange diets on glycemic control in children with type 1 diabetes. *Diabetes Care* 24:1137–1143, 2001
- Giacco R, Parillo M, Rivellese AA, Lasorella G, Giacco A, D'Episcopo L, Riccardi G: Long-term dietary treatment with increased amounts of fiber-rich low-glycemic index natural foods improves blood glucose control and reduces the number of hypoglycemic events in type 1 diabetic patients. *Diabetes Care* 23:1461–1466, 2000
- Brand J, Colagiuri S, Crossman S, Allen A, Roberts D, Truswell A: Low-glycemic index foods improve long-term glycemic control in NIDDM. *Diabetes Care* 14:95–102, 1991
- Collier G, Giudici S, Salmusky J, Wolever T, Helman G, Wesson V: Low glycaemic index starchy food improve glucose control and lower serum cholesterol in diabetic children. *Diab Nutr Metab* 1:11–18, 1988